Vericel (VCEL) Retained Earnings (2010 - 2026)
Vericel (VCEL) posted Retained Earnings of -$380.4 million for Q2 2026, up 0.58% sequentially from -$382.6 million in Q1 2026, and up 5.98% YoY from -$358.9 million in Q2 2025.
Vericel (VCEL) Retained Earnings (2010 - 2026) Analysis & Trends
Vericel has reported Retained Earnings for 17 years, with the latest figure at -$380.4 million in Q2 2026.
- Quarterly Retained Earnings rose 5.98% year-over-year to -$380.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$380.4 million (up 5.98% YoY) and the FY2025 annual result came in at -$376.3 million, up 4.21% from the prior year.
- Retained Earnings climbed to -$380.4 million in Q2 2026 per VCEL's latest filing, from -$382.6 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$376.3 million in Q4 2025 and troughed at -$416.2 million in Q3 2023.
- A 5-year average of -$400.4 million and a median of -$403.6 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings declined 4.67% in 2022, then gained 5.98% in 2026.
- Over 5 years, Retained Earnings stood at -$400.0 million in 2022, then slipped by 0.8% to -$403.2 million in 2023, then advanced by 2.57% to -$392.8 million in 2024, then increased by 4.21% to -$376.3 million in 2025, then fell by 1.09% to -$380.4 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$380.4 million, -$382.6 million, and -$376.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | -380.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -380.40 Mn |
| Mar 31, 2026 | -382.60 Mn |
| Dec 31, 2025 | -376.30 Mn |
| Sep 30, 2025 | -399.50 Mn |
| Jun 30, 2025 | -404.60 Mn |
| Mar 31, 2025 | -404.06 Mn |
| Dec 31, 2024 | -392.82 Mn |
| Sep 30, 2024 | 359,000.00 |
| Jun 30, 2024 | -411.72 Mn |
| Mar 31, 2024 | -407.04 Mn |
| Dec 31, 2023 | -100,000.00 |
| Sep 30, 2023 | -416.17 Mn |
| Jun 30, 2023 | -621,000.00 |
| Mar 31, 2023 | -407.49 Mn |
| Dec 31, 2022 | -400.00 Mn |
| Sep 30, 2022 | -405.90 Mn |
| Jun 30, 2022 | -855,000.00 |
| Mar 31, 2022 | -390.40 Mn |
| Dec 31, 2021 | -383.29 Mn |
| Sep 30, 2021 | -23,000.00 |